216 related articles for article (PubMed ID: 25590378)
21. Donor ABCB1 genetic polymorphisms influence epithelial-to-mesenchyme transition in tacrolimus-treated kidney recipients.
Bloch J; Hazzan M; Van der Hauwaert C; Buob D; Savary G; Hertig A; Gnemmi V; Frimat M; Perrais M; Copin MC; Broly F; Noël C; Pottier N; Cauffiez C; Glowacki F
Pharmacogenomics; 2014 Dec; 15(16):2011-24. PubMed ID: 25521359
[TBL] [Abstract][Full Text] [Related]
22. Impact of MDR1 and CYP3A5 on the oral clearance of tacrolimus and tacrolimus-related renal dysfunction in adult living-donor liver transplant patients.
Fukudo M; Yano I; Yoshimura A; Masuda S; Uesugi M; Hosohata K; Katsura T; Ogura Y; Oike F; Takada Y; Uemoto S; Inui K
Pharmacogenet Genomics; 2008 May; 18(5):413-23. PubMed ID: 18408564
[TBL] [Abstract][Full Text] [Related]
23. Pharmacogenetic study of ABCB1 and CYP3A5 genes during the first year following heart transplantation regarding tacrolimus or cyclosporine levels.
Jordán de Luna C; Herrero Cervera MJ; Sánchez Lázaro I; Almenar Bonet L; Poveda Andrés JL; Aliño Pellicer SF
Transplant Proc; 2011; 43(6):2241-3. PubMed ID: 21839244
[TBL] [Abstract][Full Text] [Related]
24. The Cytochrome P450 3A5 Non-Expressor Kidney Allograft as a Risk Factor for Calcineurin Inhibitor Nephrotoxicity.
Udomkarnjananun S; Townamchai N; Chariyavilaskul P; Iampenkhae K; Pongpirul K; Sirichindakul B; Panumatrassamee K; Vanichanan J; Avihingsanon Y; Eiam-Ong S; Praditpornsilpa K
Am J Nephrol; 2018; 47(3):182-190. PubMed ID: 29539600
[TBL] [Abstract][Full Text] [Related]
25. The P450 oxidoreductase *28 SNP is associated with low initial tacrolimus exposure and increased dose requirements in CYP3A5-expressing renal recipients.
de Jonge H; Metalidis C; Naesens M; Lambrechts D; Kuypers DR
Pharmacogenomics; 2011 Sep; 12(9):1281-91. PubMed ID: 21770725
[TBL] [Abstract][Full Text] [Related]
26. The distribution of genetic polymorphism of CYP3A5, CYP3A4 and ABCB1 in patients subjected to renal transplantation.
Vavić N; Rančić N; Cikota-Aleksić B; Magić Z; Cimeša J; Obrenčević K; Radojević M; Mikov M; Dragojević-Simić V
Vojnosanit Pregl; 2016 Jul; 73(7):663-7. PubMed ID: 29314799
[TBL] [Abstract][Full Text] [Related]
27. CYP3A5 and CYP3A4, but not ABCB1 polymorphisms affect tacrolimus dose-adjusted trough concentrations in kidney transplant recipients.
Kurzawski M; Dąbrowska J; Dziewanowski K; Domański L; Perużyńska M; Droździk M
Pharmacogenomics; 2014 Feb; 15(2):179-88. PubMed ID: 24444408
[TBL] [Abstract][Full Text] [Related]
28. The genetic polymorphisms of POR*28 and CYP3A5*3 significantly influence the pharmacokinetics of tacrolimus in Chinese renal transplant recipients.
Zhang JJ; Liu SB; Xue L; Ding XL; Zhang H; Miao LY
Int J Clin Pharmacol Ther; 2015 Sep; 53(9):728-36. PubMed ID: 26227094
[TBL] [Abstract][Full Text] [Related]
29. Expression of CYP3A5 and P-glycoprotein in renal allografts with histological signs of calcineurin inhibitor nephrotoxicity.
Metalidis C; Lerut E; Naesens M; Kuypers DR
Transplantation; 2011 May; 91(10):1098-102. PubMed ID: 21544031
[TBL] [Abstract][Full Text] [Related]
30. Tacrolimus dose, blood concentrations and acute nephrotoxicity, but not CYP3A5/ABCB1 genetics, are associated with allograft tacrolimus concentrations in renal transplant recipients.
Sallustio BC; Noll BD; Hu R; Barratt DT; Tuke J; Coller JK; Russ GR; Somogyi AA
Br J Clin Pharmacol; 2021 Oct; 87(10):3901-3909. PubMed ID: 33646566
[TBL] [Abstract][Full Text] [Related]
31. The donor ABCB1 (MDR-1) C3435T polymorphism is a determinant of the graft glomerular filtration rate among tacrolimus treated kidney transplanted patients.
Tavira B; Gómez J; Díaz-Corte C; Coronel D; Lopez-Larrea C; Suarez B; Coto E
J Hum Genet; 2015 May; 60(5):273-6. PubMed ID: 25673014
[TBL] [Abstract][Full Text] [Related]
32. Comparison of pharmacokinetics and pharmacogenetics of once- and twice-daily tacrolimus in the early stage after renal transplantation.
Niioka T; Satoh S; Kagaya H; Numakura K; Inoue T; Saito M; Narita S; Tsuchiya N; Habuchi T; Miura M
Transplantation; 2012 Nov; 94(10):1013-9. PubMed ID: 23073468
[TBL] [Abstract][Full Text] [Related]
33. Personalizing initial calcineurin inhibitor dosing by adjusting to donor CYP3A-status in liver transplant patients.
Monostory K; Tóth K; Kiss Á; Háfra E; Csikány N; Paulik J; Sárváry E; Kóbori L
Br J Clin Pharmacol; 2015 Dec; 80(6):1429-37. PubMed ID: 26271661
[TBL] [Abstract][Full Text] [Related]
34. Pharmacogenomic associations in ABCB1 and CYP3A5 with acute kidney injury and chronic kidney disease after myeloablative hematopoietic cell transplantation.
Woodahl EL; Hingorani SR; Wang J; Guthrie KA; McDonald GB; Batchelder A; Li M; Schoch HG; McCune JS
Pharmacogenomics J; 2008 Aug; 8(4):248-55. PubMed ID: 17700595
[TBL] [Abstract][Full Text] [Related]
35. Population pharmacokinetic-pharmacogenetic model of tacrolimus in the early period after kidney transplantation.
Han N; Ha S; Yun HY; Kim MG; Min SI; Ha J; Lee JI; Oh JM; Kim IW
Basic Clin Pharmacol Toxicol; 2014 May; 114(5):400-6. PubMed ID: 24238261
[TBL] [Abstract][Full Text] [Related]
36. Progressive decline in tacrolimus clearance after renal transplantation is partially explained by decreasing CYP3A4 activity and increasing haematocrit.
de Jonge H; Vanhove T; de Loor H; Verbeke K; Kuypers DR
Br J Clin Pharmacol; 2015 Sep; 80(3):548-59. PubMed ID: 26114223
[TBL] [Abstract][Full Text] [Related]
37. Influence of CYP3A5 and MDR1 polymorphisms on tacrolimus concentration in the early stage after renal transplantation.
Zhang X; Liu ZH; Zheng JM; Chen ZH; Tang Z; Chen JS; Li LS
Clin Transplant; 2005 Oct; 19(5):638-43. PubMed ID: 16146556
[TBL] [Abstract][Full Text] [Related]
38. Impact of CYP3A5 and MDR1(ABCB1) C3435T polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients.
Tada H; Tsuchiya N; Satoh S; Kagaya H; Li Z; Sato K; Miura M; Suzuki T; Kato T; Habuchi T
Transplant Proc; 2005 May; 37(4):1730-2. PubMed ID: 15919447
[TBL] [Abstract][Full Text] [Related]
39. Using genetic and clinical factors to predict tacrolimus dose in renal transplant recipients.
Wang P; Mao Y; Razo J; Zhou X; Wong ST; Patel S; Elliott E; Shea E; Wu AH; Gaber AO
Pharmacogenomics; 2010 Oct; 11(10):1389-402. PubMed ID: 21047202
[TBL] [Abstract][Full Text] [Related]
40. CYP3A5 and ABCB1 polymorphisms in living donors do not impact clinical outcome after kidney transplantation.
Yang L; de Winter BC; van Schaik RH; Xie RX; Li Y; Andrews LM; Shuker N; Bahmany S; Koch B; van Gelder T; Hesselink DA
Pharmacogenomics; 2018 Jul; 19(11):895-903. PubMed ID: 29991328
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
